Parkman Healthcare Partners LLC Acquires 93,201 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Parkman Healthcare Partners LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 21.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 532,172 shares of the company’s stock after purchasing an additional 93,201 shares during the period. Parkman Healthcare Partners LLC’s holdings in Nurix Therapeutics were worth $10,026,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in Nurix Therapeutics by 2.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company’s stock worth $585,000 after acquiring an additional 642 shares during the last quarter. Corebridge Financial Inc. increased its holdings in Nurix Therapeutics by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company’s stock worth $658,000 after acquiring an additional 770 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in Nurix Therapeutics by 0.7% in the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company’s stock worth $2,159,000 after acquiring an additional 785 shares during the last quarter. US Bancorp DE increased its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares during the last quarter. Finally, Summit Investment Advisors Inc. increased its holdings in Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after acquiring an additional 877 shares during the last quarter.

Nurix Therapeutics Stock Down 4.4%

Shares of NRIX stock opened at $9.73 on Wednesday. The stock has a market cap of $741.78 million, a price-to-earnings ratio of -3.37 and a beta of 2.23. The business’s fifty day moving average is $11.32 and its 200 day moving average is $17.18. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. During the same period in the prior year, the firm posted ($0.76) earnings per share. Equities research analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the transaction, the insider now owns 61,516 shares of the company’s stock, valued at approximately $707,434. This represents a 5.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at $488,660.76. This trade represents a 14.73% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on NRIX. JPMorgan Chase & Co. reduced their target price on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Stifel Nicolaus reduced their target price on Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. Leerink Partnrs raised Nurix Therapeutics to a “hold” rating in a report on Monday, March 17th. Needham & Company LLC reissued a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Finally, Stephens reissued an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, Nurix Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.